In ccRCC, the von Hippel-Lindau gene (VHL) alteration is common,drugs that modulate the downstream targets of pVHL/HIF and PI3K/AKT/mTOR pathways have been used for ccRCC treatment. This evidence concerns the gene VHL and nonpapillary renal cell carcinoma.